Immune deficiencies, infection, and systemic immune disordersThe long road to optimal management for chronic granulomatous disease
References (14)
Chronic granulomatous disease
Hematol Oncol Clin North Am
(2013)- et al.
Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease
J Allergy Clin Immunol
(2012) - et al.
Gene therapy for PIDs: progress, pitfalls and prospects
Gene
(2013) - et al.
Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation
J Allergy Clin Immunol
(2013) - et al.
Clinical features, long-term follow-up and outcome of a large cohort of patients with Chronic Granulomatous Disease: an Italian multicenter study
Clin Immunol
(2008) - et al.
Genetic, biochemical, and clinical features of chronic granulomatous disease
Medicine
(2000) - et al.
Chronic granulomatous disease. Report on a national registry of 368 patients
Medicine
(2000)
Cited by (9)
Chronic granulomatous disease: Three cases with different presentations
2015, Revista Chilena de PediatriaAdvances in basic and clinical immunology in 2013
2014, Journal of Allergy and Clinical ImmunologyCitation Excerpt :The authors emphasized that severity of clinical presentation is associated with residual nicotinamide adenine dinucleotide phosphate but not with the specific gene that is mutated and should be considered for assessment of prognosis and use of HSCT. Notarangelo56 commented on the long road to optional management of patients with CGD and predicted better outcomes with improvement in methods of HCST and gene therapy. Horn and Cowan57 reviewed the published literature concerning outcomes of HSCT for SCID.
Gut microbiota–host interactions in inborn errors of immunity
2021, International Journal of Molecular SciencesHematopoietic Stem Cell Transplantation in Primary Immunodeficiency Diseases: Current Status and Future Perspectives
2019, Frontiers in PediatricsAllogeneic hematopoietic cell transplantation for chronic granulomatous disease: Controversies and state of the art
2018, Journal of the Pediatric Infectious Diseases Society
Disclosure of potential conflict of interest: L. D. Notarangelo is on advisory boards for the Immune Disease Institute and Meyer Hospital Florence; is employed by Children's Hospital Boston; has received grants from the National Institutes of Health, the March of Dimes, and the Jeffrey Modell Foundation; and has received royalties from UpToDate.